Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011081 | 0.84 | GAA (0.42) | HCAR2DYRK1ANPC1MAPTRAB9A | |
| SCHEMBL9140451 | 0.79 | HCAR2 (0.54) | HCAR2DAODYRK1ANPC1MAPT | |
| SCHEMBL19732648 | 0.79 | — | — | |
| SCHEMBL2865249 | 0.78 | HCAR2 (0.56) | HCAR2NPC1MAPTRAB9AGFER | |
| SCHEMBL1706467 | 0.75 | — | — | |
| SCHEMBL5599955 | 0.73 | HCAR2 (0.82) | HCAR2DAOHCAR3 | |
| Hydrochloric Acid SCHEMBL1707357 | 0.73 | NPC1 (0.54) | HCAR2DYRK1ANPC1MAPTRAB9A | |
| SCHEMBL17950142 | 0.72 | — | — | |
| SCHEMBL23500955 | 0.72 | — | — | |
| SCHEMBL4521656 | 0.71 | DAO (0.37) | HCAR2DAOIGF1RFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | HCAR2 1017/4885DAO 4285/4885DYRK1A 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.